BioSpace News Archive

Today the Association for Vascular Access (AVA) and B. Braun Medical Inc. (B. Braun) announced a long-term collaboration to improve training on the placement of peripheral intravenous catheters (PIVCs).

Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies delivered via the revolutionary oral mucosal immunotherapy treatment platform, is proud to announce its participation in three upcoming conferences:

Through genetic sequencing and targeted treatment, researchers from Children’s Hospital of Philadelphia (CHOP) have resolved a severe lymphatic disorder in a young woman with kaposiform lymphangiomatosis (KLA), a complex and rare disorder that causes lymphatic vessels around the heart and lung to leak fluid, causing breathing difficulties, infections, and often death.

miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it has conducted an internal review of preliminary topline data from its Phase 2 SOLAR clinical trial of cobomarsen in patients with Cutaneous T-Cell Lymphoma (CTCL).

DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, will be presenting a company overview and will participate in 1x1 meetings at the Virtual 7th Solebury Trout Fall Private Company Showcase on Thursday, October 15th, 2020 at 12:00 pm PDT.

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, has scheduled the release of its 2020 third quarter financial results for Thursday, October 29, 2020 before the market opens.

The National Organization on Disability (NOD) Announces 2020 Leading Disability Employers at Event Marking the 30th Anniversary of the Americans with Disabilities Act

McKesson Corporation (NYSE:MCK) will release its second quarter fiscal 2021 financial results before market open on Tuesday, November 3, 2020.

Amgen (NASDAQ: AMGN) today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 126 patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), who had failed a median of two prior lines of anti-cancer therapies (immunotherapy and/or chemotherapy).

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2020 financial results on Thursday, October 29, 2020, prior to its earnings call at 8:00 a.m. ET